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ABSTRACT 99 
Importance: The prevalence of cardiometabolic multimorbidity is increasing. 100 
Objective: To estimate reductions in life expectancy associated with cardiometabolic 101 
multimorbidity. 102 
Design, Setting, and Participants: We calculated age-and sex-adjusted mortality rates and 103 
hazard ratios (HRs) using individual-participant data from the Emerging Risk Factors Collaboration 104 
(ERFC; 689,300 participants; 91 cohorts; years of baseline surveys: 1960-2007; latest follow-up: 105 
2013; 128,843 deaths). We compared HRs with those from UK Biobank (499,808 participants; 106 
years of baseline survey: 2006-2010; latest follow-up: 2013; 7995 deaths). We estimated 107 
cumulative survival by applying calculated age-specific HRs for mortality to contemporary US age-108 
specific death rates. 109 
Exposure: History of ≥2 of the following: diabetes mellitus, stroke, myocardial infarction (MI). 110 
Main Outcomes: All-cause mortality and estimated reductions in life expectancy.  111 
Results: In ERFC participants without diabetes, stroke, or MI at baseline (“reference group”), the 112 
all-cause mortality rate adjusted to age 60 years was 6.8 per 1000 person-years. Mortality rates 113 
were 15.6 with diabetes only, 16.1 with stroke only, 16.8 with MI only, 32.0 with both diabetes 114 
and MI, 32.5 with both diabetes and stroke, 32.8 with both stroke and MI, and 59.5 with diabetes, 115 
stroke, and MI. Compared to the reference group, HRs (95% CI) for all-cause mortality were 1.9 116 
(1.8-2.0) with diabetes only; 2.1 (2.0-2.2) with stroke only; 2.0 (1.9-2.2) with MI only; 3.7 (3.3-117 
4.1) with both diabetes and MI, 3.8 (3.5-4.2) with both diabetes and stroke, 3.5 (3.1-4.0) with 118 
both stroke and MI, and 6.9 (5.7-8.3) with diabetes, stroke and MI. HRs from the ERFC were 119 
similar to those from the more recently-recruited UK Biobank. HRs were little changed after 120 
further adjustment for markers of established intermediate pathways (e.g., lipids, blood pressure) 121 
and lifestyle factors (e.g., smoking, diet). At age 60 years, a history of a combination of any two 122 
conditions was associated with 12 years of reduced life expectancy; a history of three conditions 123 
was associated with 15 years of reduced life expectancy. 124 
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Conclusions and Relevance: Mortality associated with a history of diabetes, stroke, or MI was 125 
similar for each condition. As any combination of these conditions was associated with 126 
multiplicative mortality risk, life expectancy was substantially lower in people with multimorbidity. 127 
  128 
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INTRODUCTION 129 
The prevalence of cardiometabolic multimorbidity (defined here as a history of ≥2 of diabetes, 130 
stroke, myocardial infarction [MI]) is increasing rapidly.1-3 Considerable evidence exists about the 131 
mortality risk of having any one of these conditions alone.4-7 However, evidence is sparse about 132 
life expectancy among people who have two or three cardiometabolic conditions concomitantly. 133 
Valid estimation of the associations of cardiometabolic multimorbidity with mortality requires 134 
comparison of people with multimorbidity with participants within the same cohorts who did not 135 
have any of the conditions at baseline. However, few population cohorts have had sufficient 136 
power, detail, and longevity to enable such comparisons.8-14 137 
 138 
We aimed to provide reliable estimates of the associations of cardiometabolic multimorbidity with 139 
mortality and reductions in life expectancy. We analyzed individual-participant data in the 140 
Emerging Risk Factors Collaboration (ERFC) on 689,300 participants recruited during 1960-2007 141 
into 91 prospective cohorts that have recorded mortality during prolonged follow-up. We 142 
compared results with those from UK Biobank, a prospective cohort study of 499,808 participants 143 
recruited during 2006-2010.  144 
145 
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METHODS 146 
Overall design  147 
Our analysis involved several inter-related components (eFigure 1). First, we quantified 148 
associations of cardiometabolic multimorbidity with all-cause mortality. To maximize power, we 149 
analyzed data from the ERFC in which a total of about 129,000 deaths have accrued. Second, we 150 
compared results from the ERFC with those from UK Biobank. UK Biobank recruited participants 151 
more recently than the ERFC, and had accrued about 8000 deaths at the time of this analysis. 152 
Third, we estimated reductions in life expectancy associated with cardiometabolic multimorbidity 153 
by applying results from the ERFC to contemporary US death rates. Fourth, we placed our findings 154 
in the context of previous relevant studies identified through a systematic review.  155 
 156 
Data sources 157 
Both the ERFC and UK Biobank have been described previously15-17. Prospective cohort studies 158 
contributing to the ERFC were included in this analysis if they met all the following criteria: 1) had 159 
recruited participants on the basis of informed consent, 2) had recorded information about the 160 
diagnosis of diabetes, stroke, and MI at the baseline survey, 3) did not select participants on the 161 
basis of having previous chronic disease (including cardiovascular disease and diabetes), 4) 162 
recorded cause-specific deaths, and 5) had accrued more than 1 year of follow-up. Details of 163 
contributing studies in the ERFC are presented in eTable 1 and eAppendix 2. eTable 2 provides 164 
information on methods used to characterize diagnosis of diabetes, stroke, and MI at the baseline 165 
survey. The contributing studies classified deaths according to the primary cause (or, in its 166 
absence, the underlying cause), on the basis of coding from the International Classification of 167 
Diseases, revisions 8 through 10, to at least three digits, or according to study-specific 168 
classification systems. Classification of deaths was based on death certificates, supplemented in 169 
53 studies by medical records, findings on autopsy, and other sources. The date of latest 170 
mortality follow-up was April 2013. 171 
 172 
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In UK Biobank, information on a baseline history of diabetes, stroke, and MI was available for 173 
499,808 participants recruited from 22 centres throughout the United Kingdom (eAppendix 3). 174 
After giving consent, participants provided biological samples and completed a touch-screen 175 
questionnaire, a computer-assisted interview, and a physical examination. Participants have been 176 
linked with death records of the UK Office for National Statistics through National Health Service 177 
identification numbers. Deaths were classified according to the primary cause (or, in its absence, 178 
the underlying cause), on the basis of coding from the International Classification of Diseases 10, 179 
to at least three digits. The date of latest mortality follow-up was November 2013. 180 
 181 
eAppendix 4 provides details of our systematic review of population-based prospective studies 182 
reported between January 1970 and April 2015. No language restrictions were applied to 183 
publications. Studies were not eligible for the review if they had contributed data to the 184 
ERFC.8;13;18 Two investigators (PW and LOK) extracted and cross-checked information from 185 
publications according to a pre-specified protocol, with disagreements resolved by EDA. 186 
 187 
Approval was provided by the Cambridgeshire ethics review committee.  188 
 189 
Statistical analysis 190 
For both the ERFC and UK Biobank, we categorized participants into eight mutually exclusive 191 
groups according to baseline disease, ie: 1) diabetes only; 2) stroke only; 3) MI only; 4) diabetes 192 
and MI only; 5) diabetes and stroke only; 6) stroke and MI only; 7) diabetes, stroke and MI; 8) 193 
none of these (reference group). We assessed associations of these baseline groups with risk of 194 
death from any cause.  195 
 196 
Hazard ratios (HRs) were calculated using Cox proportional-hazards regression models. Because 197 
the principal objective of our study was to estimate reductions in life expectancy associated with 198 
having different combinations of cardiometabolic multimorbidity, our primary analysis calculated 199 
HRs stratified by sex and adjusted for age only. As a secondary objective was to explore the 200 
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extent to which markers of some established intermediate pathways (i.e., total and HDL 201 
cholesterol, blood pressure, body-mass index) and lifestyle factors (i.e., smoking, diet, 202 
socioeconomic status) could explain associations between cardiometabolic multimorbidity and 203 
mortality, subsidiary analyses calculated HRs adjusted for these additional factors. In the ERFC, 204 
HRs were calculated using a 2-stage approach, with estimates calculated separately within each 205 
study before pooling across studies by random-effects meta-analysis using an extension of the 206 
DerSimonian and Laird procedure.16;19 Participants were included in analyses irrespective of 207 
previous non-fatal events. For each specific cause of death, outcomes were censored if a 208 
participant was lost to follow-up, died from other causes, or reached the end of the follow-up 209 
period. The proportional hazards assumptions was satisfied for all-cause mortality (eFigure 2). 210 
We used the I2 statistic to quantify between-study heterogeneity and the Wald test to assess 211 
interactions. 212 
 213 
Since age-specific mortality rates cannot be directly obtained from a 2-stage approach using Cox 214 
regression models (ie, these models estimate instantaneous probability of death), we used a 2-215 
level mixed-effects Poisson regression model, with random study intercept, adjusted for baseline 216 
disease status, sex and age-at-risk (linear and quadratic terms) and interactions of age-at-risk 217 
with the preceding variables. This Poisson regression model was used to obtain mortality rates 218 
adjusted to age 60 years (i.e., marginal effects).  219 
 220 
eAppendix 5 provides detail of the methods used to estimate reductions in life expectancy. 221 
Briefly, estimates of cumulative survival from 40 years of age onwards among the eight baseline 222 
disease groups were calculated by applying cause-specific mortality HRs from the ERFC (specific 223 
to age-at-risk and sex) to the detailed mortality component of the CDC WONDER database of the 224 
US Centers for Disease Control and Prevention, which recorded almost 10 million deaths among 225 
over 305 million individuals during 2007-2010.20;21 We modeled results throughout middle-age 226 
and old age, giving specific consideration to HRs with cardiometabolic multimorbidity recorded by 227 
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age 60, the period of life when multimorbidity becomes increasingly common22. Analyses involved 228 
Stata (version 12.0), 2-sided P-values, and used a significance level of P<0.05.  229 
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RESULTS 230 
Emerging Risk Factors Collaboration  231 
The mean age of participants at baseline was 53 (SD 9) years; 51% were women (Table 1). The 232 
large majority were enrolled in Europe (69%) or North America (24%) (eTable 1). At enrollment, 233 
24,677 (3.6%) participants had a history of diabetes only, 8583 (1.2%) stroke only, 21,591 234 
(3.1%) MI only, 3233 (0.5%) both diabetes and MI, 1321 (0.2%) both diabetes and stroke, 1836 235 
(0.3%) both stroke and MI, and 541 (0.1%) with diabetes, stroke, and MI. During 8.83 million 236 
person-years at risk (median follow-up 12.8 [5th and 95th percentile: 4.0-29.5] years), there were 237 
128,843 deaths (50,595 vascular, 39,266 cancer, 30,664 other causes, 8318 unknown or ill-238 
defined; eTable 1).  239 
 240 
In the reference group, the sex-adjusted mortality rate at age 60 years was 6.8 (95% CI 6.2-7.4) 241 
per 1000 person-years at risk. By contrast, age- and sex-adjusted mortality rates were 15.6 242 
(14.1-17.0) with diabetes only, 16.1 (14.4-17.8) with stroke only, 16.8 (15.2-18.3) with MI only, 243 
32.0 (28.1-35.9) with both diabetes and MI, 32.5 (27.0-37.9) with both diabetes and stroke, 32.8 244 
(28.1-37.6) with both stroke and MI, and 59.5 (47.0-71.9) with diabetes, stroke, and MI. 245 
Compared with the reference group, HRs for mortality, adjusted for age and sex only, were 1.9 246 
(1.8-2.0) with diabetes only, 2.1 (2.0-2.2) with stroke only, 2.0 (1.9-2.2) with MI only, 3.7 (3.3-247 
4.1) with both diabetes and MI, 3.8 (3.5-4.2) with both diabetes and stroke, 3.5 (3.1-4.0) with 248 
both stroke and MI, and 6.9 (5.7-8.3) in people with diabetes, stroke, and MI (Figure 1). HRs 249 
with a history of ≥2 conditions were generally consistent with multiplicative effects (P>0.05 for 250 
deviation from multiplicative effects), with the exception of the HR with a history of stroke and MI 251 
(P<0.001). HRs were stronger among women than in men for patients with diabetes only, stroke 252 
only, or the combination of diabetes and MI (P<0.001; eFigure 3). HRs were little changed after 253 
additional adjustment for smoking (Table 2). HRs attenuated slightly after further adjustment for 254 
total and HDL cholesterol, systolic blood pressure, and body-mass index. In people with all three 255 
conditions at baseline, HRs, adjusted for age and sex only, were: 11.8 (9.6-14.6) for 256 
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cardiovascular mortality, 2.1 (1.5-2.9) for cancer mortality, and 7.9 (6.6-9.6) for the aggregate of 257 
nonvascular, noncancer deaths (eFigure 4).  258 
 259 
Broadly similar HRs to those noted above were observed in analyses that: used alternative 260 
definitions of baseline disease (eFigure 5); were restricted to studies that supplemented death 261 
certificates with additional information (eFigure 6); excluded the initial 5 years of follow-up 262 
(eFigure 7); or used fixed-effect meta-analysis (eFigure 8). HRs for mortality appeared to 263 
decline somewhat with increasing calendar year of baseline study enrollment (eFigure 9). 264 
 265 
UK Biobank 266 
The mean age at baseline was 57 (SD 8) years; 55% were women (Table 1). At enrollment, 267 
18,549 (3.7%) participants had a history of diabetes only, 6835 (1.4%) stroke only, 8770 (1.8%) 268 
MI only, 2036 (0.4%) both diabetes and MI, 966 (0.2%) both diabetes and stroke, 688 (0.1%) 269 
both stroke and MI, and 230 (0.05%) with diabetes, stroke, and MI. During 2.39 million person-270 
years at risk (median follow-up 4.8 [IQR: 4.1-5.5] years), there were 7995 deaths. Compared 271 
with the reference group, HRs for mortality, adjusted for age and sex only, were: 1.6 (1.5-1.8) 272 
with diabetes only, 2.1 (1.9-2.4) with stroke only, 2.1 (1.9-2.3) with MI only, 4.3 (3.7-5.0) with 273 
both diabetes and MI, 3.9 (3.1-4.9) with both diabetes and stroke, 3.8 (2.9-4.9) with both stroke 274 
and MI, and 6.0 (4.2-8.7) in people with diabetes stroke, and MI (Figure 2 & eTable 3). HRs 275 
were little changed after additional adjustment for smoking, systolic blood pressure, body-mass 276 
index, diet, and socioeconomic status (Table 2).  277 
 278 
Estimated reductions in life expectancy 279 
We estimated that at age 60 years men with any two of the cardiometabolic conditions we studied 280 
would, on average, have a reduced life expectancy of 12 years, and men with all three conditions 281 
would have a reduced life expectancy of 14 years (Figure 3 & eTable 4). For women at age 60 282 
years, the corresponding estimates were 13 and 16 years of life lost, respectively. When 283 
calculated for patients at younger ages, estimated reductions in life expectancy were greater than 284 
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for older patients (eg, 23 years of life were estimated to be lost for men at age 40 with three 285 
conditions, compared with 20 years of life lost for men at age 50 with three conditions). 286 
Estimated reductions in life expectancy in people with MI only were greater for men than women; 287 
estimated reductions in life expectancy in people with diabetes only were greater for women 288 
(Figure 3 & eTable 4). On average, about 59% of the survival difference associated with 289 
cardiometabolic multimorbidity in men was attributed to excess cardiovascular deaths, and the 290 
remainder to excess nonvascular, noncancer deaths (36%), cancer deaths (4%), and unclassified 291 
deaths (1%). By contrast, for women, 45% of the estimated survival difference was attributed to 292 
excess cardiovascular deaths, and the remainder by nonvascular, noncancer deaths (49%), 293 
excess cancer deaths (5%), and unclassified deaths (2%) (eFigure 10). Broadly similar results 294 
were observed when modeling involved cause-specific death rates from the EU (eFigure 11).  295 
 296 
Systematic review  297 
We could not identify any previous relevant reports of all-cause mortality that had investigated 298 
participants having the combination of diabetes, stroke, and MI, nor any previous relevant reports 299 
of participants having the combination of stroke and MI. We identified only one previous relevant 300 
report on the combination of diabetes and stroke, albeit of limited statistical power.23 By contrast, 301 
we identified five previous reports on the combination of diabetes and MI, which generally yielded 302 
similar HRs as in the current analysis (Figure 2 & eTable 5), although none estimated reductions 303 
in life expectancy associated with such multimorbidity.9-12;14 304 
  305 
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DISCUSSION 306 
Our analysis of over 135,000 deaths accrued during prolonged follow-up of almost 1.2 million 307 
participants in population cohorts has provided estimates of reductions in life expectancy 308 
associated with different combinations of cardiometabolic multimorbidity (i.e., a history of 309 
diabetes, stroke, and/or MI). Each of our three main findings has potential implications. 310 
 311 
First, we observed HRs for mortality of about 2, 4, and 8, respectively, in people who had only 312 
one condition, or a combination of any two or three conditions that we studied. These results 313 
suggest that associations of cardiovascular disease and diabetes with mortality are multiplicative 314 
and essentially non-overlapping. This finding is consistent with previous observations that 315 
associations of diabetes with chronic disease outcomes are largely independent of major 316 
cardiovascular risk factors.5;24 Consequently, our results emphasize the importance of measures 317 
to prevent cardiovascular disease in people who already have diabetes, and, conversely, to avert 318 
diabetes in people who already have cardiovascular disease.25;26 319 
 320 
Second, our results suggest that estimated reductions in life expectancy associated with 321 
cardiometabolic multimorbidity are of similar magnitude to those previously noted for exposures 322 
of major concern to public health, such as lifelong smoking (10 years of reduced life 323 
expectancy27) and infection with human immunodeficiency virus (11 years of reduced life 324 
expectancy28;29). For example, cardiometabolic multimorbidity at age 60 years was associated 325 
with an average reduction in life expectancy of about 15 years. We estimated even greater 326 
reductions in life expectancy in patients with multimorbidity at younger ages, such as 23 years of 327 
life lost in patients with three conditions at age 40 years.  328 
 329 
Third, we noted modification by sex of associations between cardiometabolic multimorbidity and 330 
mortality. For men, the association between baseline cardiovascular disease (i.e., a history of 331 
stroke or MI) and reduced survival was stronger than for women, whereas the association 332 
between baseline diabetes and reduced survival was stronger for women. Consequently, for men 333 
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about 60% of the years of life lost from cardiometabolic multimorbidity can be attributed to 334 
cardiovascular deaths, compared to only about 45% for women. Nevertheless, for both men and 335 
women, our findings indicate that associations of cardiometabolic multimorbidity extend beyond 336 
cardiovascular mortality. Future work will seek to elucidate explanations for these interactions by 337 
sex. 338 
 339 
Our results highlight the need to balance “high-risk” approaches and population-wide strategies in 340 
order to optimize disease prevention. About 1% of the participants in the cohorts we studied had 341 
cardiometabolic multimorbidity, compared with an estimate of 3% from recent surveys in the 342 
US30;31. There are currently an estimated 10 million adults in the US and the European Union with 343 
cardiometabolic multimorbidity1;3;20;21. Nevertheless, an over-emphasis on the substantial 344 
reductions in life expectancy estimated for the subpopulation with multimorbidity could divert 345 
attention and resources away from population-wide strategies that aim to improve health for the 346 
large majority of the population.32  347 
 348 
Our study had potential limitations. Our definition of cardiometabolic multimorbidity was both 349 
pragmatically motivated (we had information available on a history of diabetes, stroke, and MI) 350 
and biologically motivated (we purposefully focused on binary disease states). However, we did 351 
not include a history of hypertension in our definition of multimorbidity because categorizing 352 
elevated blood pressure as a binary variable would necessarily underestimate the true impact of 353 
blood pressure on chronic disease, since blood pressure has a continuous log-linear relationship 354 
with the risk of cardiovascular diseases throughout its range of values.33 Furthermore, inclusion of 355 
hypertension in our definition would have created 16 possible disease combinations, too many for 356 
stable analyses even in the ERFC. We did not have access to time-varying exposure information 357 
to enable updating of multimorbidity status during follow-up. Only subsets of participants had 358 
information on some covariates, such as medication use, and dates of diagnosis of baseline 359 
conditions.  360 
 361 
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The generalizability of our results was enhanced by involvement in the ERFC of individual-362 
participant data from 91 cohorts in 18 different countries that recruited participants during 1960-363 
2007. To what extent do the HRs from the ERFC reflect the contemporary situation? Our study 364 
addressed this concern in several ways. We analyzed data in the ERFC by calendar decade, and 365 
we did not find evidence of large differences in HRs by calendar period of recruitment. We noted 366 
broadly similar findings between the ERFC and UK Biobank, which recruited participants during 367 
2006-2010. Our systematic review found that HRs reported in previous relevant publications were 368 
compatible to those in the ERFC, although previous data were sparse. Finally, in survival 369 
modeling, we applied HRs observed in the ERFC to death rates derived from the contemporary US 370 
(and, secondarily, European Union) population.  371 
 372 
CONCLUSIONS 373 
Mortality associated with a history of diabetes, stroke, or MI was similar for each condition. As any 374 
combination of these conditions was associated with multiplicative mortality risk, life expectancy 375 
was substantially lower in people with multimorbidity. 376 
  377 
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Table 1. Baseline characteristics of data from the Emerging Risk Factors Collaboration and UK Biobank contributing to the current 486 
analysis, according to participants’ disease status at baseline 487 
 488 
 489 
Disease status at baseline None Diabetes only Stroke only MI only Diabetes  
& MI 
Diabetes 
& Stroke 
Stroke  
& MI 
Diabetes, 
Stroke & MI 
        
Emerging Risk Factors Collaboration 
(91 studies, 689,300 participants)        
n 627518 (91.0) 24677 (3.6) 8583 (1.2) 21591 (3.1) 3233 (0.5) 1321 (0.2) 1836 (0.3) 541 (0.1) 
Age at survey (yrs) 52.1 (8.9) 57.3 (8.1) 50.9 (7.8) 60.5 (7.0) 69.4 (6.5) 67.7 (6.8) 69.8 (6.9) 63.8 (6.9) 
Sex, men 305031 (49) 12347 (50) 4496 (52) 14643 (68) 2121 (66) 738 (56) 1232 (67) 322 (60) 
Current smokers 197335 (31) 5343 (22) 2086 (24) 5759 (27) 515 (16) 224 (17) 412 (22) 82 (15) 
Systolic blood pressure (mmHg) 132 (19) 141 (21) 142 (22) 139 (22) 142 (22) 150 (22) 144 (23) 146 (22) 
Body mass index (kg/m2) 25.6 (4.2) 27.9 (5.3) 26.3 (4.5) 26.6 (4.3) 30.5 (4.8) 29.0 (5.2) 27.3 (4.5) 28.1 (5.1) 
Total cholesterol (mmol/l) 5.84 (1.12) 5.67 (1.18) 5.85 (1.12) 5.87 (1.15) 5.93 (1.14) 5.70 (1.18) 5.76 (1.14) 5.30 (1.15) 
HDL-C (mmol/l) 1.37 (0.39) 1.24 (0.37) 1.33 (0.40) 1.22 (0.36) 1.10 (0.34) 1.15 (0.34) 1.12 (0.37) 1.06 (0.33) 
         
UK Biobank 
(499,808 participants)         
n 461754 (92.4) 18549 (3.7) 6835 (1.4) 8770 (1.8) 2036 (0.4) 966 (0.2) 668 (0.1) 230 (0.05) 
Age at survey (yrs) 56.7 (8.1) 59.6 (7.2) 60.8 (7.0) 62.1 (6.3) 62.7 (5.7) 62.2 (6.2) 62.5 (6.1) 61.7 (6.5) 
Sex, men 202816 (44) 11184 (60) 3683 (54) 6981 (80) 1709 (84) 627 (65) 500 (75) 178 (77) 
Current smokers 47771 (10) 1983 (11) 1057 (15) 1249 (14) 277 (14) 131 (14) 145 (22) 55 (24) 
Systolic blood pressure (mmHg) 137 (19) 141 (17) 140 (19) 136 (19) 138 (19) 141 (19) 137 (20) 137 (18) 
Body mass index (kg/m2) 27.2 (4.7) 31.2 (5.9) 28.3 (4.9) 28.8 (4.6) 31.8 (5.4) 31.8 (5.9) 29.3 (5.1) 31.9 (5.3) 
Education (vocational/university) 278419 (61) 9813 (54) 3344 (50) 4127 (48) 851 (43) 409 (43) 281 (43) 89 (40) 
Meat consumption (≥2/week) 301797 (65) 13006 (70) 4555 (67) 6154 (70) 1479 (73) 672 (70) 474 (71) 158 (69) 
Fruit consumption (≥3/day) 165676 (36) 7915 (43) 2393 (35) 2966 (34) 824 (41) 433 (45) 224 (34) 99 (43) 
 490 
          Values are mean (SD) or No. (%)  491 
 492 
 493 
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Table 2. Hazard ratios for all-cause mortality in subsets of participants with information on cardiovascular risk factors and other 494 
characteristics. 495 
 496 
Disease status at baseline No. of  
participants 
No. of  
deaths 
Hazard ratio (95% CI) 
   Age and sex Age, sex, and 
smoking 
Age, sex, smoking, and 
 intermediate risk factors* 
Age, sex, smoking, 
 intermediate risk factors, 
 and other lifestyle factors† 
       
ERFC      
(68 studies, 355,639 participants, 47,067 deaths)     
Diabetes & Stroke & MI 260 165 6.2 (5.1, 7.4) 6.3 (5.2, 7.5) 6.0 (5.0, 7.1) - 
Stroke & MI 921 517 3.7 (3.1, 4.3) 3.8 (3.2, 4.4) 3.7 (3.2, 4.4) - 
Diabetes & Stroke 654 334 3.7 (3.3, 4.2) 3.9 (3.4, 4.4) 3.6 (3.2, 4.1) - 
Diabetes & MI 1,827 930 3.6 (3.1, 4.0) 3.8 (3.3, 4.4) 3.6 (3.2, 4.1) - 
MI only 12,141 4,270 2.0 (1.9, 2.1) 2.0 (1.9, 2.2) 2.0 (1.9, 2.2) - 
Stroke only 4,357 1,530 2.1 (1.9, 2.2) 2.0 (1.9, 2.2) 2.0 (1.8, 2.1) - 
Diabetes only 12,887 3,629 1.9 (1.7, 2.0) 1.9 (1.8, 2.0) 1.8 (1.7, 1.9) - 
None 322,592 35,692 1.0 (Reference) 1.0 (Reference) 1.0 (Reference) - 
       
UK Biobank       
(491,424 participants, 7,688 deaths)      
Diabetes & Stroke & MI 218 26 5.8 (3.9, 8.5) 5.2 (3.5, 7.7) 4.9 (3.3, 7.2) 4.9 (3.3, 7.2) 
Stroke & MI 638 51 3.6 (2.7, 4.7) 3.2 (2.5, 4.3) 3.1 (2.4, 4.1) 3.1 (2.3, 4.0) 
Diabetes & Stroke 919 75 3.9 (3.1, 4.9) 3.8 (3.0, 4.8) 3.6 (2.9, 4.5) 3.6 (2.8, 4.5) 
Diabetes & MI 1,943 190 4.3 (3.7, 5.0) 4.2 (3.6, 4.8) 4.0 (3.4, 4.6) 3.9 (3.4, 4.5) 
MI only 8,572 407 2.1 (1.9, 2.3) 2.0 (1.8, 2.3) 2.0 (1.8, 2.2) 2.0 (1.8, 2.2) 
Stroke only 6,632 259 2.1 (1.8, 2.4) 2.0 (1.8, 2.3) 2.0 (1.7, 2.2) 1.9 (1.7, 2.2) 
Diabetes only 17,928 504 1.6 (1.5, 1.8) 1.6 (1.5, 1.8) 1.5 (1.4, 1.7) 1.5 (1.4, 1.7) 
None 454,574 6,176 1.0 (Reference) 1.0 (Reference) 1.0 (Reference) 1.0 (Reference) 
 497 
* Intermediate risk factors available in the ERFC were: body mass index, systolic blood pressure, total and HDL cholesterol. Intermediate risk factors available in the UK Biobank were: body mass 498 
index, and systolic blood pressure. 499 
 500 
† Other lifestyle factors in the UK Biobank were: socioeconomic status (defined as education level) and diet (defined as self-reported meat and fruit consumption 501 
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Figure 1. Mortality rates and hazard ratios in the Emerging Risk Factors Collaboration for all-cause mortality, according to 
participants’ disease status at baseline 
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Mortality rates were calculated using a Poisson regression model and are sex-adjusted rates at age 60 years. Hazard ratios were calculated using a Cox proportional-hazards regression model 
and are stratified by sex and adjusted by age at baseline. Analyses were based on participants from 91 studies.  
 
Figure 2. Comparison of hazard ratios for all-cause mortality from the Emerging Risk 
Factors Collaboration with those from UK Biobank and previous reports.  
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Abbreviations: CI, confidence interval; EPESE, Hispanic Established Population for the Epidemiological Study of 
the Elderly; ERFC, Emerging Risk Factors Collaboration; HPFS, Health Professionals Follow-up Study; MI, 
myocardial infarction; NHS, Nurses' Health Study; PHS, Physicians' Health Study. *For participant-level 
analyses in the ERFC and UK Biobank, participants with the disease status indicated at baseline have been 
compared with participants within the same cohorts without diabetes, stroke, or myocardial infarction at 
baseline. For previously published studies, participants with cardiometabolic multimorbidity at baseline were 
compared with participants without any such conditions. †Used history of CHD instead of history of MI. Hazard 
ratios are adjusted for sex (when appropriate) and age, except those for EPESE and Renfrew Paisley which are 
adjusted for additional variables.  
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Figure 3. Modeling of years of life lost according to participants’ disease status at baseline 
compared to participants free of diabetes, stroke and myocardial infarction 
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Estimates of cumulative survival from 40 years of age onwards among the eight baseline disease groups were calculated 
by applying hazard ratios (specific to age-at-risk and sex) for cause-specific mortality associated with baseline disease 
status to US cause-specific death rates at 40 years of age and older. 
 
 
 
 
 
 
 
 
 
 
 
